Wu-Tang Loving Pharma CEO Also a Better Short Seller Than Chanos

Martin Shkreli is no stranger to the press. He nabbed headlines this month for paying millions for the only existing copy of the Wu-Tang Clan’s latest album. In September, he drew condemnation for raising the price of a drug for HIV patients by more than 5,000 percent. Corporate disputes and outrageous tweets added to the controversy along the way.

One thing the 32-year-old Shkreli, chief executive officer of both Turing Pharmaceuticals AG and KaloBios Pharmaceuticals Inc., doesn’t grab as many headlines for: short selling. And perhaps even less known: he’s very good at it. One ranking, by short selling data firm Activist Shorts, puts the performance of his published bearish calls above those of Citron Research, Kase Capital Management’s Whitney Tilson, Greenlight Capital and Jim Chanos’s Kynikos Associates LP.